N6-methyladenosine levels in peripheral blood RNA: a potential diagnostic biomarker for colorectal cancer

Table 1 Correlation between the levels of m⁶A and clinicopathological characteristics in CRC

Characteristics	No. of patients	Peripheral blood m⁶A levels % (mean ± SD)	P
Age
≤ 60	36	0.2884 ± 0.01005	0.3547
> 60	42	0.301 ± 0.008999	0.3547
Gender
Female	32	0.3019 ± 0.01148	0.4092
Male	46	0.2905 ± 0.008122	0.4092
Clinical stage
I	13	0.2707 ± 0.008552	0.1692
II	20	0.3164 ± 0.01441
III	31	0.2889 ± 0.01018
IV	12	0.2879 ± 0.01869
T classification
T1–T2	11	0.2773 ± 0.01684	0.3121
T3–T4	55	0.2974 ± 0.008176	0.3121
N classification
N0	25	0.2869 ± 0.01146	0.4016
N1–N2	42	0.2997 ± 0.0095	0.4016
N classification
N0–N1	47	0.2956 ± 0.009102	0.8516
N2	19	0.2925 ± 0.01294	0.8516
M classification
M0	45	0.2922 ± 0.009224	0.2933
M1	20	0.2753 ± 0.01174	0.2933
CEA (ng/mL)
< 5	50	0.2844 ± 0.008085	0.0380
≥ 5	26	0.3143 ± 0.01196	0.0380
CA19-9 (ng/mL)
< 35	61	0.2871 ± 0.007505	0.0252
≥ 35	15	0.3254 ± 0.01456	0.0252

m⁶A: N6-methyladenosine, T: tumor: N: node, M: metastasis, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9

ISSN: 1475-2867